|
|
|
|
Efficacy of a Low-Cost,inactivated Whole-Cell oral cholera vaccine: Results from 3 years of Follow-Up of a randomized,controlled trial
|
|
|
|
|
|
|
|
نویسنده
|
sur d. ,kanungo s. ,sah b. ,manna b. ,ali m. ,paisley a.m. ,niyogi s.k. ,park j.k. ,sarkar b. ,puri m.k. ,kim d.r. ,deen j.l. ,holmgren j. ,carbis r. ,rao r. ,van thu n. ,han s.h. ,attridge s. ,donner a. ,ganguly n.k. ,bhattacharya s.k. ,nair g.b. ,clemens j.d. ,lopez a.l.
|
|
منبع
|
plos neglected tropical diseases - 2011 - دوره : 5 - شماره : 10
|
|
چکیده
|
Background: killed oral cholera vaccines (ocvs) have been licensed for use in developing countries,but protection conferred by licensed ocvs beyond two years of follow-up has not been demonstrated in randomized,clinical trials. methods/principal findings: we conducted a cluster-randomized,placebo-controlled trial of a two-dose regimen of a low-cost killed whole cell ocv in residents 1 year of age and older living in 3,933 clusters in kolkata,india. the primary endpoint was culture-proven vibrio cholerae o1 diarrhea episodes severe enough to require treatment in a health care facility. of the 66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients),38 vaccinees and 128 placebo-recipients developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%ci lower bound = 53%,p<0.001). vaccine protection during the third year of follow-up was 65% (one-sided 95%ci lower bound = 44%,p<0.001). significant protection was evident in the second year of follow-up in children vaccinated at ages 1-4 years and in the third year in older age groups. conclusions/significance: the killed whole-cell ocv conferred significant protection that was evident in the second year of follow-up in young children and was sustained for at least three years in older age groups. continued follow-up will be important to establish the vaccine's duration of protection. trial registration: clinicaltrials.gov nct00289224. © 2011 sur et al.
|
|
|
|
|
آدرس
|
national institute of cholera and enteric diseases,kolkata, India, national institute of cholera and enteric diseases,kolkata, India, international vaccine institute,seoul, South Korea, national institute of cholera and enteric diseases,kolkata, India, international vaccine institute,seoul, South Korea, international vaccine institute,seoul, South Korea, national institute of cholera and enteric diseases,kolkata, India, international vaccine institute,seoul, South Korea, national institute of cholera and enteric diseases,kolkata, India, international vaccine institute,seoul, South Korea, international vaccine institute,seoul, South Korea, international vaccine institute,seoul, South Korea, university of gothenburg,gothenburg, Sweden, international vaccine institute,seoul, South Korea, shantha biotechnics,hyderabad, India, company for vaccine and biologicals,hanoi, Viet Nam, international vaccine institute,seoul,south korea,seoul national university,seoul, South Korea, university of gothenburg,gothenburg, Sweden, university of western ontario,london,on, Canada, indian council of medical research,new delhi, India, indian council of medical research,new delhi, India, national institute of cholera and enteric diseases,kolkata, India, international vaccine institute,seoul, South Korea, international vaccine institute,seoul, South Korea
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|